Clinical Trial

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-27
Trial Details
NCT Number NCT07461454
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Locally Advanced or Metastatic Breast Cancer
Enrollment 376 participants
Start Date 2026-03-17
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-26